Checked
Eikon Therapeutics, Inc.
Nasdaq: EIKN · Biological Products, (No Diagnostic Substances) · Millbrae, CA
- Last filing
- 10/26/2026
- Filings on record
- 39
Company details
As reported to the SEC
- SEC CIK
- 1861123
- Stock
- Nasdaq: EIKN
- Industry (SIC)
- Biological Products, (No Diagnostic Substances) (2836)
- Headquarters
- 230 Harriet Tubman Way, Millbrae, CA 94030
- Incorporated in
- Delaware
- Fiscal year end (SEC record)
- December 31
- Filer status
- , Emerging growth company
- Phone
- (341) 777-0566
- Employer ID (EIN)
- 84-2807586
- Last annual report
- 03/30/2026
- Last quarterly report
- 08/13/2026
No annual XBRL financial data in U.S. dollars is available for this company. Funds, very new registrants, and some foreign companies that report in other currencies do not have it. See the filings below or on EDGAR.
Federal and state records filed under the name Eikon Therapeutics, Inc.
Matched by the company name and by the subsidiary names it lists in SEC filings and other public records, after removing endings like Inc., Corp. and Holdings. Records marked Subsidiary were filed under a subsidiary name. A subsidiary that is not listed in those records is not included, and an unrelated business with the same name can appear.
Work visa sponsorship
Certified H-1B and PERM green card filings with the Department of Labor
| Employer on filing | H-1B | PERM |
|---|---|---|
| Eikon Therapeutics, Inc.Millbrae, CA | 15 | 2 |
Recent filings
39 recent filings on record; insider ownership forms (3, 4, 5 and 144) are not listed here
Swipe the table sideways to see more columns.
28 insider ownership reports (Forms 3, 4, 5 and 144) were filed about Eikon Therapeutics, Inc. in the last 12 months. They list trades by officers, directors and large holders; see them on SEC EDGAR.
Other biological products, (no diagnostic substances)
Swipe the table sideways to see more columns.
| Company | Headquarters | Revenue | Net income |
|---|---|---|---|
| Amgen IncAMGN | Thousand Oaks, CA | $36.75B | $7.71B |
| Gilead Sciences, Inc.GILD | Foster City, CA | $29.44B | $8.51B |
| Biogen Inc.BIIB | Cambridge, MA | $9.89B | $1.29B |
| Neurocrine Biosciences IncNBIX | San Diego, CA | $2.86B | $478.6M |
| Exelixis, Inc.EXEL | Alameda, CA | $2.32B | $782.6M |
| Qiagen N.V.QGEN | Pl Venlo, Netherlands | $2.09B | $424.9M |
| Moderna, Inc.MRNA | Cambridge, MA | $1.94B | -$2.82B |
| Halozyme Therapeutics, Inc.HALO | San Diego, CA | $1.4B | $316.9M |
Profile refreshed Oct 26, 2026; financials refreshed Oct 22, 2026.
Frequently asked questions
- What is Eikon Therapeutics, Inc.'s CIK number?
- Eikon Therapeutics, Inc.'s SEC Central Index Key (CIK) is 1861123.
- What is Eikon Therapeutics, Inc.'s stock ticker?
- Eikon Therapeutics, Inc. trades as Nasdaq: EIKN.
- When does Eikon Therapeutics, Inc.'s fiscal year end?
- Eikon Therapeutics, Inc.'s fiscal year end on file with the SEC is December 31.
- Where is Eikon Therapeutics, Inc. headquartered?
- Eikon Therapeutics, Inc.'s principal executive office on file with the SEC is in Millbrae, CA.
- Does Eikon Therapeutics, Inc. sponsor H-1B visas?
- Department of Labor records show 15 certified H-1B filings and 2 certified PERM filings under the name Eikon Therapeutics, Inc.
Source: U.S. Securities and Exchange Commission, EDGAR submissions and XBRL company facts · Last updated 10/26/2026